GlaxoSmithKline PLC Bonds

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

GlaxoSmithKline PLC financial leverage is the degree to which the firm utilises its fixed-income securities. Companies with high leverage are usually considered to be at financial risk. GlaxoSmithKline PLC financial risk is the risk to GlaxoSmithKline PLC stockholders that is caused by an increase in debt. In other words with a high degree of financial leverage come high interest payments which usually reduces Earnings Per Share (EPS). Please check the analysis of GlaxoSmithKline PLC Fundamentals Over Time.

Search Bonds

GlaxoSmithKline PLC Debt to Equity Ratio is decreasing as compared to previous years. The last year's value of Debt to Equity Ratio was reported at 5.38

GlaxoSmithKline PLC Bond Ratings

Total Macroaxis Rating
Very Firm
Average S&P Rating
Piotroski F Score
5  Healthy

GlaxoSmithKline PLC Debt to Cash Allocation

The company has 36.63 B in debt with debt to equity (D/E) ratio of 182.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. GlaxoSmithKline PLC has Current Ratio of 0.8 suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

GlaxoSmithKline PLC Inventories Over Time


GlaxoSmithKline PLC Corporate Bonds Issued

Issue DateMaturityCouponRef CouponS&P Rating
377372AB3 5.375%04/06/200404/15/20345.3755.375
377372AD9 5.65%05/13/200805/15/20185.650.875
377372AE7 6.375%05/13/200805/15/20386.3755.375
377372AG2 0.7%03/18/201303/18/20160.70.375
377372AH0 2.8%03/18/201303/18/20232.82.25
377372AJ6 4.2%03/18/201303/18/20434.23.0
377373AB1 0.75%05/09/201205/08/20150.750.0
377373AC9 1.5%05/09/201205/08/20171.50.375
377373AD7 2.85%05/09/201205/08/20222.852.0

GlaxoSmithKline PLC Historical Liabilities

About GlaxoSmithKline PLC Bonds and Use of Financial Leverage

GlaxoSmithKline PLC financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures the total debt position of GlaxoSmithKline PLC, including all of GlaxoSmithKline PLC's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of GlaxoSmithKline PLC assets, the company is considered highly leveraged. Understanding the composition and structure of overall GlaxoSmithKline PLC debt and outstanding corporate bonds gives a good idea as to how risky the capital structure of a business and if it is worth investing in it. Please read more on our technical analysis page.
Last ReportedProjected for 2020
Total Debt 30,508,000,000  36,630,000,000 
Debt Current 6,918,000,000  5,472,421,053 
Debt Non Current 23,590,000,000  21,672,421,053 
Issuance Repayment of Debt Securities 3,515,000,000  3,792,500,000 
Long Term Debt to Equity 2.07  2.70 
Debt to Equity Ratio 5.38  182.90 
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 99437 people.

Current Sentiment - GSK

GlaxoSmithKline PLC Investor Sentiment

Predominant part of Macroaxis users are currently bullish on GlaxoSmithKline PLC. What is your judgment towards investing in GlaxoSmithKline PLC? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check the analysis of GlaxoSmithKline PLC Fundamentals Over Time. Please also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page